HomeCompareVAXX vs VIG

VAXX vs VIG: Dividend Comparison 2026

VAXX yields 1000000.00% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VAXX wins by $4.7683925249533696e+36M in total portfolio value
10 years
VAXX
VAXX
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full VAXX calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — VAXX vs VIG

📍 VAXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVAXXVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VAXX + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VAXX pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VAXX
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, VAXX beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VAXX + VIG for your $10,000?

VAXX: 50%VIG: 50%
100% VIG50/50100% VAXX
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VAXX buys
0
VIG buys
9
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$VIG▲ Buy$1,001 - $15,0002024-05-16
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002023-12-28
Ro Khanna🏢 House$VIG▼ Sell$15,001 - $50,0002023-05-04
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
Joe Courtney🏢 House$VIG▼ Sell$1,001 - $15,0002020-10-09
K. Michael Conaway🏢 House$VIG▼ Sell$50,001 - $100,0002020-09-08
K. Michael Conaway🏢 House$VIG▲ Buy$15,001 - $50,0002020-05-19
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVAXXVIG
Forward yield1000000.00%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.7683925249533696e+36M$32.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$175.21
Total dividends collected$4.7683311610149396e+36M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VAXX vs VIG ($10,000, DRIP)

YearVAXX PortfolioVAXX Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,301$160.59+$100.00MVAXX
2$934,786,450,701$934,679,439,252.34$12,752$162.91+$934786.44MVAXX
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,370$165.02+$8165787108.56MVAXX
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,176$166.93+$66665884190957.63MVAXX
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$18,188$168.67+$508662171058048128.00MVAXX
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$20,432$170.25+$3.62723524842849e+21MVAXX
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$22,933$171.68+$2.417368115915061e+25MVAXX
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$25,720$172.98+$1.5056740286145463e+29MVAXX
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$28,827$174.15+$8.764771002818475e+32MVAXX
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$32,288$175.21+$4.7683925249533696e+36MVAXX

VAXX vs VIG: Complete Analysis 2026

VAXXStock

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Full VAXX Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this VAXX vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VAXX vs SCHDVAXX vs JEPIVAXX vs OVAXX vs KOVAXX vs MAINVAXX vs DGROVAXX vs NOBLVAXX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.